Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium-glucose co-transporter 1-mediated glucose absorption in the small intestine

被引:13
|
作者
Chan, Leo K. Y. [1 ]
Wang, Yi [1 ]
Ng, Enders K. W. [2 ]
Leung, Po Sing [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Room 609A, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Fac Med, Shatin, Hong Kong, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 03期
关键词
diabetes; glucose intolerance; NHE3; inhibitor; postprandial hyperglycaemia; HYPOGLYCEMIC AGENT; TRANSPORTER SGLT1; RECEPTOR; ENTEROCYTES; ACTIVATION; KINASE; GROWTH; NHE3;
D O I
10.1111/dom.13151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimTo elucidate the role of Na+/H+ exchanger 3 (NHE3) in sodium-glucose co-transporter 1 (SGLT1)-mediated small intestinal brush border membrane (BBM) glucose absorption and its functional implications in type 2 diabetes mellitus (T2DM). Materials and MethodsHuman jejunal samples were obtained from patients undergoing gastrectomy. C-14-glucose absorption was measured by liquid scintillation counting. NHE3 expression was suppressed by siRNA-mediated knockdown or augmented in Caco2 cells. Glucose and insulin tolerance in db/db and m+/db mice was assessed with oral and intraperitoneal glucose tolerance tests, and an intraperitoneal insulin tolerance test. Insulin resistance and -cell function were assessed using homeostatic model assessment of insulin resistance and -cell function. ResultsNHE3 expression was upregulated in db/db mouse jejunal BBM and high-glucose-treated Caco2 cells. NHE3 blockade impaired SGLT1-mediated glucose absorption in human jejunum, m+/db and db/db mouse jejunums, and Caco2 cells, via serum/glucocorticoid-regulated kinase 1 (SGK1). NHE3 knockdown suppressed SGLT1-mediated glucose uptake and reduced mRNA and protein levels of SGK1 and SGLT1, which were conversely enhanced by NHE3 overexpression. Chronic S3226 treatment diminished postprandial glucose levels and ameliorated glucose intolerance in db/db mice. ConclusionNHE3 is essential in the modulation of small intestinal BBM glucose absorption. Our findings provide a rationale for future possible clinical application of NHE3 for treatment of T2DM through reducing intestinal glucose uptake and counteracting postprandial hyperglycaemia.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 50 条
  • [1] Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions
    Zuurbier, Coert J.
    Baartscheer, Antonius
    Schumacher, Cees A.
    Fiolet, Jan W. T.
    Coronel, Ruben
    CARDIOVASCULAR RESEARCH, 2021, 117 (14) : 2699 - 2701
  • [2] Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
    Chung, Yu Jin
    Park, Kyung Chan
    Tokar, Sergiy
    Eykyn, Thomas R.
    Fuller, William
    Pavlovic, Davor
    Swietach, Pawel
    Shattock, Michael J.
    CARDIOVASCULAR RESEARCH, 2021, 117 (14) : 2794 - 2806
  • [3] Molecular regulation of the renin-angiotensin system by sodium-glucose co-transporter 2 inhibition in type 1 diabetes mellitus
    Kopecky, Chantal
    Domenig, Oliver
    Antlanger, Marlies
    Kovarik, Johannes J.
    Kaltenecker, Christopher
    Poglitsch, Marko
    Cherney, David Z.
    Saemann, Marcus D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : 169 - 169
  • [4] A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition
    Basile, Jan
    POSTGRADUATE MEDICINE, 2011, 123 (04) : 38 - 45
  • [5] Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?
    Popovic, Djordje S.
    Stoian, Anca Pantea
    Papanas, Nikolaos
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (11)
  • [6] Effect of sodium-glucose co-transporter inhibitors on arterial stiffness in patients with type 2 diabetes mellitus
    Szigeti, J.
    Bukva, M.
    Gaszner, B.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [7] The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
    Whalen, Karen
    Miller, Shannon
    St Onge, Erin
    CLINICAL THERAPEUTICS, 2015, 37 (06) : 1150 - 1166
  • [8] Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
    Dandona, Paresh
    Chaudhuri, Ajay
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [9] Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
    Jeon, Ja Young
    Kim, Dae Jung
    DIABETES & METABOLISM JOURNAL, 2024, 48 (05) : 837 - 846
  • [10] Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
    Mikhail, Nasser
    WORLD JOURNAL OF DIABETES, 2014, 5 (06): : 854 - 859